Vera Therapeutics (VERA) Stock: Buy, Sell, or Hold?
VERA - Vera Therapeutics, Inc. Class A Common Stock
$27.99
-1.06 (-3.65%)
▼
5d:
+0.39%
30d:
-16.05%
90d:
-20.44%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
10d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 20, 2026 at $30.06 · last confirmed Oct 23, 2026
Strength: 5.9/10
Get Alerted When VERA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VERA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VERA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VERA is currently trading at $27.99, which is considered oversold relative to its 30-day fair value range of $28.54 to $33.45.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $26.38, while resistance sits at $31.84. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: VERA scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $74.20 (+165.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $26.38, while resistance sits at $31.84. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: VERA scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $74.20 (+165.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$28.54 -
$33.45
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 165.1% below Wall St target ($74.20)
- BULLISH: Bottoming setup score 61/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$28.54 -
$33.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$26.38
Resistance Level
$31.84
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.58
Wall Street Target
$74.20
(+165.1%)
Share & Embed Analysis
Last updated: October 25, 2026 4:17 PM ET
Data refreshes hourly during market hours. Next update: 5:17 PM
Data refreshes hourly during market hours. Next update: 5:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$280 | 43 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$18 | 47 HOLD |
